Grey has advised Evolan Pharma AB in connection with the purchase of a portfolio consisting of 12 brands (Citodon, Morfin Special, Sincon, Bamse, Oliva, Karbasal, Complete, Nazamer, Ferromax, Tussin, Samin and Conotrane) from Karo Pharma. The portfolio had a turnover of SEK 62 million in 2020.

Evolan is a Swedish pharmaceutical company focused on product development, sales and marketing of pharmaceuticals.

Karo Pharma is a pharmaceutical company specialised in sales and marketing of prescription pharmaceuticals and over-the-counter products sold in pharmacies and retail. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.